MEI Pharma announces new clinical data from First-In-Human Study of ME-401
MEI Pharma, the San Diego based oncology company, have today announced new clinical data from a First-In-Human study for ME-401, a next generation oral PI3K delta inhibitor.
The First-In-Human study was conducted using Quotient Sciences’s Translational Pharmaceutics® platform. PK/PD data were collected immediately after each dose allowing for real-time decision making and manufacturing between dose groups.
The data was presented at the AACR Annual Meeting 2016 in New Orleans, in a poster entitled “Clinical Pharmacokinetics and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Administration to Healthy Volunteers”.